Use of biochemical markers to study and follow patients with osteoarthritis

被引：35

作者：

Garnero P. ^{[1
]}

机构：

[1] Synarc, Molecular Markers, Le Buroparc Batîment T4, 69003 Lyon

来源：

Current Rheumatology Reports | 2006年 / 8卷 / 1期

关键词：

Osteoarthritis; Biochemical Marker; Knee Osteoarthritis; Cartilage Oligomeric Matrix Protein; Cartilage Degradation;

D O I：

10.1007/s11926-006-0023-5

中图分类号：

学科分类号：

摘要：

Osteoarthritis is characterized by progressive destruction of articular cartilage and subchondral bone and synovial reaction. Radiologic findings that form the basis of the diagnosis of osteoarthritis are poorly sensitive to detect early disease and for monitoring progression of joint damage. Blood-based proteomic analyses suggest that biochemical alterations can be observed well before radiologic damage is evidenced. New cartilage-specific markers, including assays for type II collagen synthesis and degradation, have been developed. Recent prospective studies indicate that blood and urine levels of these new markers are associated with progression of joint damage. Biological markers respond rapidly to treatment and therefore will certainly play an important role in the development and the monitoring of disease-modifying therapies. Because osteoarthritis involves different tissues and complex biologic processes, a combination of different biochemical markers appears to be the most promising diagnostic strategy. Copyright © 2006 by Current Science Inc.

引用

页码：37 / 44

页数：7

共 38 条

[1]

Gray M.L., Eckstein F., Peterfy C., Et al., Toward imaging biomarkers for osteoarthritis, Clin Orthop Relat Res, 427, SUPPL., (2004)

[2]

Marshall K.W., Zhang H., Yager T.D., Et al., Blood-based biomarkers for detecting mild osteoarthritis, Osteoarthritis Cartilage, 13, pp. 861-871, (2005)

[3]

Liao H., Wu J., Kuhn E., Et al., Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis, Arthritis Rhem, 50, pp. 3792-3803, (2005)

[4]

Xiang Y., Sekine T., Nakamura H., Et al., Proteomic surveillance of autoimmunity in osteoarthritis: Identification of triosephosphate isomerase as an autoantigen in patients with osteoarthritis, Arthritis Rheum, 50, pp. 1511-1521, (2004)

[5]

Lamers R.J.A.N., Van Nessselrooij J.H.J., Kraus V.B., Et al., Identification of a urinary profile associated with osteoarthritis, Osteoarthritis Cartilage, 13, pp. 162-168, (2005)

[6]

Ling Q.M., Patel D., Zhan M., Et al., Changes in selected proteins associated with osteoarthritis development in the Baltimore Longitudinal study of aging (BSLA), Arthritis Rheum, 52, SUPPL., (2005)

[7]

Garnero P., Sharif M., Charni N., Et al., A 5 year longitudinal study of type II collagen synthesis and degradation and their association with disease progression in early knee osteoarthritis, Arthritis Rheum, 52, SUPPL., (2005)

[8]

Rousseau J.C., Sandell L.J., Delmas P.D., Garnero P., Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide. Human reproduction, Methods Mol Med, 101, pp. 25-38, (2004)

[9]

Garnero P., Desmarais S., Charni N., Percival M.D., The type II collagen fragments HELIX-II and CTX-II reveal distinct enzymatic pathways of cartilage collagen degradation: Diagnostic and therapeutic implications in rheumatoid arthritis and osteoarthritis, Arthritis Rheum, 44, SUPPL., (2005)

[10]

Charni N., Juillet F., Garnero P., Urinary type II collagen helical peptide (Helix II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis, Arthritis Rheum, 52, pp. 1081-1090, (2005)

← 1 2 3 4 →